Galena Biopharma Inc. priced an underwritten public offering of 17.5 million units of stock at $2 per unit, for gross proceeds of $35 million. The funds will be used for commercialization of Abstral (fentanyl) sublingual tablets, and to support an ongoing Phase III trial of Neuvax.